Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP

Alector, Inc. ALEC

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$21.0M
▼ 79.1% YoY
$-142.9M
$-184.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. A key component of our strategy is the development and application of our Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure across multiple therapeutic modalities. We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a Delaware corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080.

Written from the business description in Alector, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

USD 21.0M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 21.0 · Net income -142.9
100M200M-100M-200M
2017202020232025
Compound annual growth
−46.0%
−0.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −0.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−679 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -741.3% · Net -679.2%
-500%
201720212025
ROE
FY2025 · ROE -181.6%
-50%-100%-150%
201720212025
Three returns, three denominators.

Each USD of equity lost 182 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -184.1
150M300M-100M-200M
201720212025

Total assetsUSD 293.2M
EquityUSD 30.6M
CashUSD 65.8M
Gross debtUSD 9.7M
Net debtUSD -56.1M
Current ratio3.83×

The company holds more cash than debt.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ALEC, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.10.10.10.20.00.00.00.0
Operating income $B−0.2−0.1−0.2−0.1−0.0−0.2−0.1−0.1−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌
Income tax $B0.00.00.00.00.00.00.0◌◌
Net income $B−0.1−0.1−0.1−0.1−0.0−0.2−0.1−0.1−0.0
Free cash flow $B−0.2−0.2−0.2−0.00.3−0.2−0.10.1−0.0
EPS, diluted $−1.39−1.23−1.56−1.62−0.45−2.45−1.71−4.62−3.55
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−181.6−91.2−74.8−51.8−12.8−82.3———
Shares out B0.110.100.080.080.080.080.070.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image